The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.

Compositions for T cell-based immunotherapy of HIV, HIV-associated malignancies, HIV-associated viral infections, or other HIV-related complications. Modified T cells that are resistant to invasion or infection with HIV, such as T-cells modified to decrease or eliminate expression of mannosyl-oligosacharide glucosidase enzyme (MOGS). Methods for producing such compositions by expanding HIV-specific T cells from different sources to recognize multiple HIV antigens.

Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic T-cells by using B cells treated with biological response modifier; and a use thereof. The cytotoxic T-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like.

The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V32 TCRy6+ T cells and to their clinical application.

The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V32 TCRy6+ T cells and to their clinical application.

The present disclosure relates, at least in part, to mycobacterial polynucleotides and polypeptides, to fragments or variants thereof, to cells comprising the mycobacterial polynucleotides and polypeptides, to cells comprising the mycobacterial polynucleotides and polypeptides, that are engineered to expand T-cells ex vivo, and to methods of use thereof.

Disclosed are method of producing IL-4 exposed M2 macrophage exosomes comprising culturing macrophage or macrophage precursor cells with IL-4 in culture media, and isolating exosomes from the culture media, wherein the isolated exosomes are IL-4 exposed M2 macrophage exosomes enriched with miR-21, miR-99a, miR-146b and miR378a. Disclosed are methods of reprogramming macrophages and/or adipocytes comprising exposing the macrophages and/or adipocytes to IL-4 exposed M2 macrophage exosomes, wherein immune and/or metabolic properties are altered in the macrophages and/or adipocytes. Methods of treating with IL-4 exposed M2 macrophage exosomes.

Methods and compositions are provided herein for generating tumor targeted lymphocytes and/or tumor infiltrating lymphocytes and/or tumor targeted natural killer (NK) cells for use in the treatment of a cancer or an infectious disease. Also provided herein are methods of making and using the same.

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).